LifeScan

Last updated
LifeScan, Enterprises LLC.
Industry Medical devices
Founded1981;45 years ago (1981)
Headquarters
Malvern, Pennsylvania
Area served
Global
RevenueUS$1.5 billion(2017) [1]
Number of employees
2,400(2020) [2]
Parent Platinum Equity

LifeScan Enterprises LLC. is a diagnostic systems manufacturer with products focusing on the diabetes market, specifically blood glucose monitoring systems. Corporate headquarters in Malvern, Pennsylvania.

Contents

History

LifeScan was established in 1981. [3] It was acquired by Johnson & Johnson (J&J) in 1986, [2] [4] and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. [1] The divestiture completed in October 2018. [1] [5]

LifeScan manufactures and markets the OneTouch Ultra and OneTouch Verio families of products for home use. [1] The company philosophy is to "create a world without limits for people with diabetes." During its existence, LifeScan revolutionized blood glucose monitoring by introduction of its "One Touch" systems. Originally, the measurement was made using a test strip which changed color depending on the glucose content of a blood sample, and LifeScan rose to become the world-leading producer of such systems in the early 1990s. Later, the measurement technology was changed to electrochemistry, but LifeScan maintained a leading position in the industry.

LifeScan has facilities in Inverness, Scotland; and Cabo Rojo, Puerto Rico. Animas Corporation of West Chester, Pennsylvania, which produced insulin pumps for people with diabetes, was acquired by Johnson & Johnson in 2006 and now closed, reported to LifeScan.

LifeScan, which employed 2400 people as of early 2018, was the central part of J&J's diabetes device business. [2] J&J announced plans to exit from the diabetes device market in 2017, including divesting LifeScan. [2] In January 2018, there were reports of Chinese investors expressing interest in purchasing the company for US$3 to 4 billion, while in March, Platinum Equity offered the far smaller sum of US$2.1 billion for the unit. [2] [6]

On July 15, 2025, LifeScan filed for Chapter 11 bankruptcy protection as part of a plan to be taken over by its creditors. The company listed assets and liabilities between $1 billion and $10 billion. [7] LifeScan Enterprises LLC. emerged from bankruptcy on December 8, 2025, now operating under LifeScan Enterprises LLC. formerly LifeScan, Inc. [8]

References

  1. 1 2 3 4 Nawrat, Allie (June 15, 2018). "Johnson & Johnson sells LifeScan to Platinum Equity". Pharmaceutical Technology. Verdict Media Limited. Retrieved June 16, 2018.
  2. 1 2 3 4 5 Panchadar, Arjun (16 March 2018). "Johnson & Johnson nears diabetes device exit with $2.1 billion LifeScan sale". Reuters. Additional reporting by Caroline Humer and Munsif Vengattil; S D'Souza, P Berlowitz (editors). Retrieved 17 March 2018.
  3. ↑ "LifeScan Inc - Company Profile and News". Bloomberg.com. Retrieved 30 April 2024.
  4. ↑ About Us | LifeScan, Inc." LifeScan. Retrieved on September 18, 2014.
  5. ↑ LaVito, Angelica (October 16, 2018). "Johnson & Johnson beats expectations as cancer drugs, new baby care products help boost sales". CNBC .
  6. ↑ "Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc". Content Lab - U.S. 16 March 2018.
  7. ↑ Ma, Dorothy (July 12, 2025). "Platinum-Backed LifeScan Files Bankruptcy to Hand Over Control". Bloomberg. Retrieved July 15, 2025.
  8. ↑ Alexander, Timothy (20 December 2025). "LifeScan slashes debt, exits Chapter 11 with new owners and fresh momentum". MSN. Retrieved 2 January 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.